Akoya Biosciences (AKYA)
(Delayed Data from NSDQ)
$3.20 USD
+0.07 (2.24%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.19 -0.01 (-0.31%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AKYA 3.20 +0.07(2.24%)
Will AKYA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AKYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKYA
Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
AKYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for AKYA
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session
Akoya's PhenoCycler, PhenoImager platforms selected by MANIFEST Consortium
Akoya Biosciences chairman Robert Shepler to leave role, Scott Mendel to succeed
Piper Sandler Sticks to Their Buy Rating for Akoya Biosciences (AKYA)